ZHENGYE BIOTECHNOLOGY HOLDIN (ZYBT) Stock Fundamental Analysis
USA - NASDAQ:ZYBT - KYG989MS1016 - Common Stock
2.2004 USD
+0.05 (+2.34%)
We assign a fundamental rating of 5 out of 10 to ZYBT. ZYBT was compared to 192 industry peers in the Pharmaceuticals industry. Both the profitability and the financial health of ZYBT get a neutral evaluation. Nothing too spectacular is happening here. ZYBT has a correct valuation and a medium growth rate.
1. Profitability
1.1 Basic Checks
In the past year ZYBT was profitable.
In the past year ZYBT had a positive cash flow from operations.
1.2 Ratios
The Return On Assets of ZYBT (7.96%) is better than 89.53% of its industry peers.
ZYBT has a Return On Equity of 13.83%. This is amongst the best in the industry. ZYBT outperforms 88.48% of its industry peers.
Looking at the Return On Invested Capital, with a value of 12.67%, ZYBT belongs to the top of the industry, outperforming 91.10% of the companies in the same industry.
Measured over the past 3 years, the Average Return On Invested Capital for ZYBT is below the industry average of 15.35%.
The 3 year average ROIC (10.57%) for ZYBT is below the current ROIC(12.67%), indicating increased profibility in the last year.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 7.96% | ||
| ROE | 13.83% | ||
| ROIC | 12.67% |
ROA(3y)5.86%
ROA(5y)N/A
ROE(3y)10.42%
ROE(5y)N/A
ROIC(3y)10.57%
ROIC(5y)N/A
1.3 Margins
ZYBT's Profit Margin of 12.95% is amongst the best of the industry. ZYBT outperforms 86.91% of its industry peers.
ZYBT's Profit Margin has declined in the last couple of years.
ZYBT's Operating Margin of 16.66% is amongst the best of the industry. ZYBT outperforms 85.86% of its industry peers.
ZYBT's Operating Margin has declined in the last couple of years.
The Gross Margin of ZYBT (54.00%) is better than 64.40% of its industry peers.
In the last couple of years the Gross Margin of ZYBT has declined.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 16.66% | ||
| PM (TTM) | 12.95% | ||
| GM | 54% |
OM growth 3Y-29.5%
OM growth 5YN/A
PM growth 3Y-34.62%
PM growth 5YN/A
GM growth 3Y-5.78%
GM growth 5YN/A
2. Health
2.1 Basic Checks
The Return on Invested Capital (ROIC) is just above the Cost of Capital (WACC), so ZYBT is still creating some value.
ZYBT has about the same amout of shares outstanding than it did 1 year ago.
Compared to 1 year ago, ZYBT has an improved debt to assets ratio.
2.2 Solvency
An Altman-Z score of 3.36 indicates that ZYBT is not in any danger for bankruptcy at the moment.
With a decent Altman-Z score value of 3.36, ZYBT is doing good in the industry, outperforming 71.73% of the companies in the same industry.
The Debt to FCF ratio of ZYBT is 6.51, which is on the high side as it means it would take ZYBT, 6.51 years of fcf income to pay off all of its debts.
With an excellent Debt to FCF ratio value of 6.51, ZYBT belongs to the best of the industry, outperforming 80.63% of the companies in the same industry.
ZYBT has a Debt/Equity ratio of 0.02. This is a healthy value indicating a solid balance between debt and equity.
Looking at the Debt to Equity ratio, with a value of 0.02, ZYBT is in line with its industry, outperforming 55.50% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.02 | ||
| Debt/FCF | 6.51 | ||
| Altman-Z | 3.36 |
ROIC/WACC1.6
WACC7.94%
2.3 Liquidity
A Current Ratio of 1.31 indicates that ZYBT should not have too much problems paying its short term obligations.
ZYBT has a Current ratio of 1.31. This is in the lower half of the industry: ZYBT underperforms 74.35% of its industry peers.
A Quick Ratio of 0.88 indicates that ZYBT may have some problems paying its short term obligations.
Looking at the Quick ratio, with a value of 0.88, ZYBT is doing worse than 79.06% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 1.31 | ||
| Quick Ratio | 0.88 |
3. Growth
3.1 Past
ZYBT shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 21.94%, which is quite impressive.
ZYBT shows a strong growth in Earnings Per Share. Measured over the last years, the EPS has been growing by 528.02% yearly.
ZYBT shows a strong growth in Revenue. In the last year, the Revenue has grown by 43.18%.
Measured over the past years, ZYBT shows a very strong growth in Revenue. The Revenue has been growing by 854.79% on average per year.
EPS 1Y (TTM)21.94%
EPS 3Y528.02%
EPS 5YN/A
EPS Q2Q%-64.04%
Revenue 1Y (TTM)43.18%
Revenue growth 3Y854.79%
Revenue growth 5YN/A
Sales Q2Q%-11.95%
3.2 Future
No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
3.3 Evolution
No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
4. Valuation
4.1 Price/Earnings Ratio
With a Price/Earnings ratio of 18.34, ZYBT is valued on the expensive side.
Based on the Price/Earnings ratio, ZYBT is valued cheaper than 83.25% of the companies in the same industry.
Compared to an average S&P500 Price/Earnings ratio of 25.89, ZYBT is valued a bit cheaper.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 18.34 | ||
| Fwd PE | N/A |
4.2 Price Multiples
Based on the Enterprise Value to EBITDA ratio, ZYBT is valued cheaper than 86.39% of the companies in the same industry.
Based on the Price/Free Cash Flow ratio, ZYBT is valued a bit cheaper than 77.49% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 55.75 | ||
| EV/EBITDA | 10.55 |
4.3 Compensation for Growth
ZYBT has a very decent profitability rating, which may justify a higher PE ratio.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2YN/A
EPS Next 3YN/A
5. Dividend
5.1 Amount
No dividends for ZYBT!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
NASDAQ:ZYBT (11/14/2025, 8:00:02 PM)
2.2004
+0.05 (+2.34%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)
Earnings (Next)
Inst Owners0.89%
Inst Owner ChangeN/A
Ins Owners6.53%
Ins Owner ChangeN/A
Market Cap104.28M
Revenue(TTM)303.21M
Net Income(TTM)39.27M
AnalystsN/A
Price TargetN/A
Short Float %3.93%
Short Ratio0.28
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Yearly Dividend0.05
Dividend Growth(5Y)N/A
DP40.8%
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)N/A
PT rev (3m)N/A
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)N/A
EPS NY rev (3m)N/A
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 18.34 | ||
| Fwd PE | N/A | ||
| P/S | 2.44 | ||
| P/FCF | 55.75 | ||
| P/OCF | 18.03 | ||
| P/B | 2.61 | ||
| P/tB | 2.83 | ||
| EV/EBITDA | 10.55 |
EPS(TTM)0.12
EY5.45%
EPS(NY)N/A
Fwd EYN/A
FCF(TTM)0.04
FCFY1.79%
OCF(TTM)0.12
OCFY5.55%
SpS0.9
BVpS0.84
TBVpS0.78
PEG (NY)N/A
PEG (5Y)N/A
Graham Number1.51
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 7.96% | ||
| ROE | 13.83% | ||
| ROCE | 14.13% | ||
| ROIC | 12.67% | ||
| ROICexc | 13.42% | ||
| ROICexgc | 14.4% | ||
| OM | 16.66% | ||
| PM (TTM) | 12.95% | ||
| GM | 54% | ||
| FCFM | 4.38% |
ROA(3y)5.86%
ROA(5y)N/A
ROE(3y)10.42%
ROE(5y)N/A
ROIC(3y)10.57%
ROIC(5y)N/A
ROICexc(3y)10.67%
ROICexc(5y)N/A
ROICexgc(3y)11.51%
ROICexgc(5y)N/A
ROCE(3y)11.8%
ROCE(5y)N/A
ROICexgc growth 3Y-33.64%
ROICexgc growth 5YN/A
ROICexc growth 3Y-34.32%
ROICexc growth 5YN/A
OM growth 3Y-29.5%
OM growth 5YN/A
PM growth 3Y-34.62%
PM growth 5YN/A
GM growth 3Y-5.78%
GM growth 5YN/A
F-Score7
Asset Turnover0.61
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.02 | ||
| Debt/FCF | 6.51 | ||
| Debt/EBITDA | 0.06 | ||
| Cap/Depr | 114.94% | ||
| Cap/Sales | 9.16% | ||
| Interest Coverage | 12.67 | ||
| Cash Conversion | 54.97% | ||
| Profit Quality | 33.8% | ||
| Current Ratio | 1.31 | ||
| Quick Ratio | 0.88 | ||
| Altman-Z | 3.36 |
F-Score7
WACC7.94%
ROIC/WACC1.6
Cap/Depr(3y)102.94%
Cap/Depr(5y)N/A
Cap/Sales(3y)10.29%
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)21.94%
EPS 3Y528.02%
EPS 5YN/A
EPS Q2Q%-64.04%
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)43.18%
Revenue growth 3Y854.79%
Revenue growth 5YN/A
Sales Q2Q%-11.95%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y12.17%
EBIT growth 3Y573.13%
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-63.72%
FCF growth 3Y1249.56%
FCF growth 5YN/A
OCF growth 1Y-14.81%
OCF growth 3Y988.8%
OCF growth 5YN/A
ZHENGYE BIOTECHNOLOGY HOLDIN / ZYBT FAQ
What is the ChartMill fundamental rating of ZHENGYE BIOTECHNOLOGY HOLDIN (ZYBT) stock?
ChartMill assigns a fundamental rating of 5 / 10 to ZYBT.
Can you provide the valuation status for ZHENGYE BIOTECHNOLOGY HOLDIN?
ChartMill assigns a valuation rating of 4 / 10 to ZHENGYE BIOTECHNOLOGY HOLDIN (ZYBT). This can be considered as Fairly Valued.
What is the profitability of ZYBT stock?
ZHENGYE BIOTECHNOLOGY HOLDIN (ZYBT) has a profitability rating of 6 / 10.
Can you provide the financial health for ZYBT stock?
The financial health rating of ZHENGYE BIOTECHNOLOGY HOLDIN (ZYBT) is 5 / 10.